Denali Therapeutics Files 8-K for Regulation FD Disclosure
Ticker: DNLI · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
TL;DR
Denali Therapeutics filed an 8-K for a Reg FD disclosure on 3/5/25. No major news, just compliance.
AI Summary
Denali Therapeutics Inc. filed an 8-K on March 5, 2025, reporting a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself. The company is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This filing indicates Denali Therapeutics is making a public disclosure under Regulation FD, ensuring fair and simultaneous dissemination of material information to all investors.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not report any new material events, financial changes, or executive actions.
Key Players & Entities
- Denali Therapeutics Inc. (company) — Registrant
- March 5, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- South San Francisco, California (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 5, 2025.
In which state is Denali Therapeutics Inc. incorporated?
Denali Therapeutics Inc. is incorporated in Delaware.
What is the address of Denali Therapeutics Inc.'s principal executive offices?
The address of Denali Therapeutics Inc.'s principal executive offices is 161 Oyster Point Blvd., South San Francisco, California, 94080.
Does this filing report any specific material events or financial updates?
No, this filing specifically states it is for a Regulation FD Disclosure and does not detail specific material events or financial updates beyond that classification.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 regarding Denali Therapeutics Inc. (DNLI).